Mutations: I am on Orserdu (elacestrant... - SHARE Metastatic ...

SHARE Metastatic Breast Cancer

6,809 members8,426 posts

Mutations

Healthplus1 profile image
1 Reply

I am on Orserdu (elacestrant) for a ESR1 mutation and feeling great but my CA27-29 tumor marker numbers continue to rise. Prior to this medication I was on Capecitabine for a PIC3 mutation and prior to that Piqray. Does any one know what meds work to target both mutations simultaneously?

Written by
Healthplus1 profile image
Healthplus1
To view profiles and participate in discussions please or .
Read more about...
1 Reply
HelenWi profile image
HelenWi

Piqray is a targeted therapy and is given for pic3 mutation. I think you can take Orserdu with targeted therapies. Capecitabine is a chemo drug and is typically given by itself.

There is a new drug Trucap that requires you to have one of three mutations, one of which is pic3. Truqap is a targeted therapy. So you might want to ask your oncologist about that.

Best wishes ,

Helen

Not what you're looking for?

You may also like...

Rising ESR1 Mutations During Aromatase Inhibitor and Palbociclib Therapy

From Oncology October 15, 2022: Published in The Lancet Oncology 29.09.2022 "This phase...
Hazelgreen profile image

Who has ESR1 how are you doing

I just developed the ESR1 mutation and went on Faslodex and switched to Kisquali. I was wondering...
DDIL1 profile image

Pik3 CA mutation

So I recently had a liquid biopsy done because after seven years on Ibrance and letrozole my cancer...
gerisplace profile image

Liquid biopsy approved

Making progress. The biopsy for Pic mutation has been approved. The test will check for 100...
Francesca10 profile image

Moderation team

See all
Jslanovich profile image
JslanovichAdministrator

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.